Call for Abstract

Acadamia
  • University of Montreal, Canada

    University of Washington, USA

    Tanzania Vaccine Institute, Tanzania

    Alexandria University, Egypt

    Lanzhou Veterinary Research Institute, China

    Sassari University School of Medicine, Italy

    The University of Melbourne, Australia

    Technical University of Braunschweig, Germany

    Tsukuba Primate Research Center, Japan

    Vaccines and Sera Torlak, Serbia

    Emory University, USA

    Faculdade de Medicina Santo, Brazil

    Centro de Ingenieria Genetica y Biotecnologia, Cuba

    University of KwaZulu-Natal, Belgium

    National Health Research Institute, Taiwan

    Korea University, Korea

    Center for Genetic Engineering and Biotechnology, Cuba

    Indonesian Technical Advisory Committee on Immunization, Indonesia

    Walter Reed Army Institute of Research, USA

    USAMRIID, USA

    Karolinska Institutet, Sweden

    Gulu University, Uganda

    The Royal Children’s Hospital, Australia

    University of Groningen, Netherlands

    Central Institute for Research on Goats, India

    INSERM, France

    University of Sarajevo, Bosnia and Herzegovina

    University of British Columbia, Canada

    Temple University Center for Biotechnology, USA

    UC Davis School of Medicine, USA

    The Scripps Research Institute, USA

    The University of Tokyo, Japan

    Texas Biomedical Research Institute, USA

    Flinders University, Australia

    The George Washington University, USA

    The University of Adelaide, South Australia

    University of Michigan Medical School, USA

    University of Louisville, USA

    National Centre for Biotechnology, Spain

    Pontifical Universtity of Salamanca, Spain

    Universidade Federal de Goias, Brazil

    JJ Strossmayer University, Croatia

    Tehran University of Medical Sciences, Iran

    Medical University of Vienna, Austria

    University of Bedfordshire, UK

    University of Oxford, UK

    The Tazuke Kofukai Medical Research Institute, Japan

    Pasteur Institute of Iran, Iran

    Palacky University, Czech Republic

    The University of Western Ontario, Canada

    Chonbuk National University, South Korea

Business
  • Liquidia Technologies Inc., USA

    Profectus BioSciences, Inc., USA

    Prokarium Ltd., UK

    FluGen Inc., USA

    Novartis Vaccines, USA

    Merck & Co., Inc., USA

    Arbovax Inc., USA

    Merck Millipore, Europe

    Sanofi Pasteur, USA

    UNIVAC llc, Belgium

    Bavarian Nordic, Germany

    VALNEVA, Austria

    Cellular Technology Limited, USA

    Celldex Therapeutics, USA

    Serum Institute of India, India

    Vedantra Pharmaceuticals, USA

    Shanghai Zerun Biotechnology Co .,Ltd. China

    GenPhar Inc., USA

    InnaVirVax, USA

    West Pharmaceutical Services, USA

    Inovio Pharmaceuticals, USA

    VaxInnate Corporation, USA

    Vaxart, Inc., USA

    Iliad Biotechnologies, Scotland

    European Institute of Innovation and Technology, Europe

    REIMS, France

    International Vaccine Institute, Korea

    Micronutrient Initiative, Bangladesh

    Slovak Academy of Sciences, Solvakia

  •  

5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, will be organized around the theme “Vaccine Research: From Bench to Bedside”

Vaccines Asia Pacific-2015 is comprised of 22 tracks and 121 sessions designed to offer comprehensive sessions that address current issues in Vaccines Asia Pacific-2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
  • Track 1-2Diphtheria and tetanus toxoids usage in pediatrics
  • Track 1-3Administration and routes of administration of toxoids
  • Track 1-4Innovative toxoid vaccine development
  • Track 1-5Maternal immunization
  • Track 1-6Others
  • Track 3-1Challenges and Innovation
  • Track 3-2Planning
  • Track 3-3Business Development of Animal Vaccines
  • Track 3-4Business Development of Human Vaccines
  • Track 3-5Phyto vaccines
  • Track 4-1Peptide Based vaccines
  • Track 4-2Protein based vaccines
  • Track 4-3Others
  • Track 5-1Progress and challenges
  • Track 5-2Others
  • Track 6-1Cancer Therapeutic Vaccines
  • Track 6-2Vaccines for Preventive cancer
  • Track 6-3Others
  • Track 7-1Chickenpox vaccines
  • Track 7-2Diphtheria vaccines
  • Track 7-3Polio vaccines
  • Track 7-4Hib Vaccines
  • Track 7-5Hepatitis A vaccines
  • Track 7-6Hepatitis B vaccines
  • Track 7-7Flu vaccines
  • Track 7-8Measles vaccines
  • Track 7-9Mumps vaccines
  • Track 7-10Pertussis vaccines
  • Track 7-11Pneumococcal vaccines
  • Track 7-12Rotavirus vaccines
  • Track 7-13Rubella vaccines
  • Track 7-14Tetanus vaccines
  • Track 7-15Others
  • Track 8-1Mucosal Vaccines Design
  • Track 8-2Mucosal Vaccines Delivery
  • Track 8-3Others
  • Track 9-1Dendritic cell based vaccines and development
  • Track 9-2Recombinent vector based immunization
  • Track 9-3DNA Vaccination
  • Track 9-4T-cell receptor peptide vaccines
  • Track 9-5Targeted bacterial protein identification
  • Track 9-6Others
  • Track 10-1HIV vaccine
  • Track 10-2Ebola vaccine
  • Track 10-3Cancer vaccination
  • Track 10-4Vaccine for severe acute respiratory syndrome
  • Track 10-5Need of vaccination for major diseases
  • Track 10-6Others
  • Track 11-1Immunization and its side effects in geriatrics
  • Track 11-2Vaccine dosing and administration in older adults
  • Track 11-3Herpes zoster vaccine
  • Track 11-4Pneumococcal polysaccharide vaccine
  • Track 11-5Contraindications and precautions during vaccination in geriatrics
  • Track 11-6Risk factors in geriatric immunization
  • Track 11-7Others
  • Track 12-1Recent trends in vaccines development path
  • Track 12-2Current technologies using in vaccines discovery
  • Track 12-3New vaccines against infectious diseases
  • Track 12-4Recent technologies in modifying bacterial genome
  • Track 13-1Role of nanotechnology in vaccine delivery
  • Track 13-2Hepatitis B virus spread and control
  • Track 13-3Recombinant technology usage
  • Track 13-4Virus-like particles as vaccines, vectors and adjutants
  • Track 13-5Vaccines and its target compositions
  • Track 13-6Others
  • Track 14-1Safety considerations in vaccination
  • Track 14-2Vaccines and vaccination knowledge
  • Track 14-3Health care outcomes of different aged people vaccinated
  • Track 14-4Safety and efficacy of vaccines
  • Track 14-5Vaccines and vaccination- health care improvement.
  • Track 14-6Others
  • Track 15-1Preclinical stage development and factors affecting
  • Track 15-2Clinical stage process
  • Track 15-3Vaccines efficacy testing
  • Track 15-4Manufacture of the vaccine to Good Manufacturing Practice standards
  • Track 15-5Complications and consequences affecting vaccine development
  • Track 15-6Others
  • Track 16-1Yellow fever: Epidemiology and prevention
  • Track 16-2Typhoid fever vaccination
  • Track 16-3Advantage of live attenuated vaccines
  • Track 16-4Risk factors in unsing live attenuated vaccines
  • Track 16-5Tubercular vaccination
  • Track 16-6Cancer Therapeutic Vaccination
  • Track 16-7Others
  • Track 17-1Conjugated vaccine discovery and translation of new vaccine technology
  • Track 17-2Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants
  • Track 17-3Production of Conjugate Vaccines Using Recombinant DNA Technology
  • Track 17-4Manufacturing of Conjugate Vaccines
  • Track 17-5Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
  • Track 17-6Others
  • Track 18-1Designing of adjutvants
  • Track 18-2Rationale selection of adjuvants
  • Track 18-3Skin delivery techniques
  • Track 18-4Adjuvant interactions
  • Track 18-5BeneficialAdjuvents
  • Track 18-6Others
  • Track 19-1Bovine vaccine technology
  • Track 19-2Pet vaccines and vaccination
  • Track 19-3Animal health outcomes
  • Track 19-4Animal diseases and vaccination
  • Track 19-5Current status of veterinary vaccines
  • Track 19-6Others
  • Track 20-1Whooping cough Vaccines in pregnant women
  • Track 20-2Immunization before pregnancy
  • Track 20-3Immunization during pregnancy
  • Track 20-4Consequences of halting vaccination in pregnancy
  • Track 20-5Chiropractic vaccination care in women and pregnancy
  • Track 20-6Others
  • Track 21-1Major discoveries in carbohydrate based vaccines
  • Track 21-2Glycomics- Vaccine Discoveries
  • Track 21-3Identification, synthesis and evaluation of unique glycan epitopes
  • Track 21-4Targeting the surface carbohydrates of infectious agents
  • Track 21-5Role of carbohydrate-based vaccines in cancer therapy
  • Track 21-6Others
  • Track 22-1New approaches to combat bacterial pathogens
  • Track 22-2Public health concerns in vaccination
  • Track 22-3Contraindications of vaccinations
  • Track 22-4Vaccines formulation and technologies used in conjugated vaccines
  • Track 22-5Vaccine resistance and need of Next-Gen Conjugate Vaccines
  • Track 22-6Others